Financial performance 2008/2007
Download Excel table (see terms of use page)
OUR FINANCIAL PERFORMANCE| 2008 | 2007 | 2006 | 2008 compared to 2007 | 2007 compared to 2006 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Sales $m |
CER growth $m |
Growth due to exchange effect $m |
Sales $m |
CER growth $m |
Growth due to exchange effect $m |
Sales $m |
CER growth % |
Reported growth % |
CER growth % |
Reported growth % |
| Pulmicort | 1,495 | 7 | 34 | 1,454 | 128 | 34 | 1,292 | – | 3 | 10 | 13 |
| Symbicort | 2,004 | 346 | 83 | 1,575 | 265 | 126 | 1,184 | 22 | 27 | 22 | 33 |
| Rhinocort | 322 | (41) | 9 | 354 | (16) | 10 | 360 | (12) | (9) | (4) | (2) |
| Oxis | 71 | (21) | 6 | 86 | (9) | 7 | 88 | (24) | (17) | (10) | (2) |
| Accolate | 73 | (4) | 1 | 76 | (6) | 1 | 81 | (5) | (4) | (7) | (6) |
| Other | 163 | (9) | 6 | 166 | 7 | 13 | 146 | (5) | (2) | 5 | 14 |
| Total | 4,128 | 278 | 139 | 3,711 | 369 | 191 | 3,151 | 7 | 11 | 12 | 18 |
PERFORMANCE 2008
Reported performance
Sales in Respiratory and Inflammation therapy area (R&I) increased by 11% to $4,128 million from $3,711 million in 2007.
Performance – CER growth rates
R&I sales grew by 7% at CER.
Sales of Symbicort grew by 22% to $2,004 million. In the US, sales of the product were $255 million, up 410%. Product trial rate among target specialist physicians is now approaching 90%; these specialists are now starting more than 30% of patients new to combination therapy on Symbicort. More than half of target primary care physicians have prescribed Symbicort, and share of new patient starts is just under 18%. Overall, Symbicort share of new prescriptions for fixed combinations reached 11.7% in the week ending 16 January, with market share among patients newly starting combination treatment at 18.3%. Symbicort sales in other markets in the year were $1,749 million, up 9%. Symbicort SMART has now been approved in 91 markets.
Pulmicort sales were flat at $1,495 million, with US sales up 2% as the generic competition from the Teva product affected quarter four sales. US sales for Pulmicort were down 15% to $260 million in the fourth quarter and Pulmicort Respules sales were down 18% as a result of the “at risk” launch of generic budesonide inhalation suspension (BIS) on 18 November. The patent litigation between Teva and AstraZeneca was subsequently settled on 26 November. The agreement allows Teva to commence sales of BIS under an exclusive licence from AstraZeneca beginning 15 December 2009. The agreement also provided that any product already shipped by Teva would remain in the market to be further distributed and dispensed. As a result, Teva products accounted for nearly 15% of total prescriptions for BIS products dispensed during the fourth quarter, including a 40% share in December 2008. US sales for Pulmicort for the full year were $982 million. Pulmicort Respules accounted for around 90% of total Pulmicort sales in the US. Sales of Pulmicort in Rest of World were down 2% for the full year to $513 million.
PERFORMANCE 2007
Reported performance
Continued growth from Symbicort drove the increase in reported sales for R&I, which grew by 18% from $3,151 million in 2006 to $3,711 million in 2007.
Performance – CER growth rates
Sales in R&I increased by 12% at CER.
Symbicort sales for the full year were up 22% to $1,575 million. Sales in Western Europe were up 16%, with market share up another point in the last 12 months, aided by the roll-out of the Symbicort SMART regime. Good growth for the year was achieved in Canada (up 25%) and in Emerging Markets (up 26%). Sales in the US were $50 million since launch at the end of June 2007. Specialist physicians rapidly adopted the product; nearly 75% of allergists and more than 60% of pulmonary specialists in our target audience have prescribed Symbicort. Pulmicort sales increased by 10% to $1,454 million. US sales increased 15% for the full year to $964 million. Pulmicort Respules sales in the US were up more than 20% for the full year, on estimated volume growth of 15%. Of the approximately six million children under the age of eight who are treated for asthma, more than one million benefit from treatment with Pulmicort Respules. Sales in other markets were unchanged for the year.
Rhinocort sales fell by 4% to $354 million, with a 9% decline in the US being compensated by small gains elsewhere.
